Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBT: 2022-2025

Historic EBT for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$30.0 million.

  • Phathom Pharmaceuticals' EBT rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported EBT of -$30.0 million as of Q3 2025, which was up 60.39% from -$75.7 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' EBT's 5-year high stood at -$30.0 million during Q3 2025, with a 5-year trough of -$94.3 million in Q1 2025.
  • Moreover, its 3-year median value for EBT was -$75.7 million (2025), whereas its average is -$66.9 million.
  • Per our database at Business Quant, Phathom Pharmaceuticals' EBT crashed by 123.20% in 2024 and then skyrocketed by 64.98% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' EBT (Quarterly) stood at -$55.0 million in 2022, then slumped by 44.76% to -$79.6 million in 2023, then climbed by 6.36% to -$74.5 million in 2024, then surged by 64.98% to -$30.0 million in 2025.
  • Its EBT stands at -$30.0 million for Q3 2025, versus -$75.7 million for Q2 2025 and -$94.3 million for Q1 2025.